European Union - English - EMA (European Medicines Agency)

gilead sciences international limited - cidofovir - cytomegalovirus retinitis - antivirals for systemic use - vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (aids) and without renal dysfunction. vistide should be used only when other agents are considered unsuitable.,

Israel - English - Ministry of Health

tzamal bio-pharma ltd - tretinoin - capsules - tretinoin 10 mg - tretinoin - induction of remission in acute promyelocytic leukemia.

Israel - English - Ministry of Health

abic marketing ltd, israel - acitretin - capsules - acitretin 10 mg - acitretin - severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.

Israel - English - Ministry of Health

abic marketing ltd, israel - acitretin - capsules - acitretin 25 mg - acitretin - severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - tretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: purified water; glycerol; yellow beeswax; iron oxide yellow; gelatin; titanium dioxide; iron oxide red; soya oil; partially hydrogenated soya oil; hydrogenated soya oil; maize starch; sorbitol; mannitol - vesanoid should be used for induction of remission in acute promyelocytic leukemia (apl; fab classification aml-m3). previously untreated patients as well as patients who relapse after or are refractory to standard chemotherapy (daunorubicin and cytosine arabinoside (ara-c)or equivalent therapies) may be treated with vesanoid. following complete remission, consolidation full dose chemotherapy should be employed. a loss of responsiveness to vesanoid has been reported among patients maintained on vesanoid. the median time to relapse for patients maintained on vesanoid is 4 to 6 months.

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - neoral is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. neoral has been used in combination with azathioprine and corticosteroids. neoral is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. neoral can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. neoral is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. while rebound rarely occurs, most patients will experience relapse with neoral as with other therapies upon cessation of treatment. neoral is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive neoral. psoriasis patients who are treated with neoral should not receive concomitant puva or uvb therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive neoral. although no adequate and well-controlled studies have been completed in children, transplant recipients as young as one year of age have received neoral with no unusual adverse effects. the safety and efficacy of neoral treatment in children with juvenile rheumatoid arthritis or psoriasis below the age of 18 have not been established. in rheumatoid arthritis clinical trials with cyclosporine, 17.5% of patients were age 65 or older. these patients were more likely to develop systolic hypertension on therapy, and more likely to show serum creatinine rises ≥ 50% above the baseline after 3 to 4 months of therapy. clinical studies of neoral in transplant and psoriasis patients did not include a sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experiences have not identified differences in response between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

ethex corporation - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone syrup is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus acute

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - acitretin - capsule, hard - retinoids for treatment of psoriasis; acitretin

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - acitretin - capsule, hard - retinoids for treatment of psoriasis; acitretin